Onconova Therapeutics

GVK Biosciences, Onconova partner to advance new cancer drugs

Monday, January 14, 2013 01:23 PM

GVK Biosciences, a contract research and development organization, has entered into a novel joint partnership with Onconova Therapeutics, a Newtown, Penn.-based biopharmaceutical company focused on novel small molecules for oncology, to develop new drugs for cancer.

More... »


Baxter, Onconova form European licensing agreement for anti-cancer compound rigosertib

Wednesday, September 19, 2012 03:11 PM

Baxter International, a developer, manufacturer and marketer of medical products, and Onconova Therapeutics, a discoverer and developer of novel small molecule therapeutics, have entered into a European licensing agreement for rigosertib, a novel targeted anti-cancer compound currently in a phase III study for the treatment of a group of rare hematologic malignancies called myelodysplastic syndromes (MDS) and in a phase II/III study for pancreatic cancer.

More... »


Onconova extends agreement with BioClinica

Wednesday, November 30, 2011 02:54 PM
BioClinica has reported that Onconova Therapeutics has extended agreements using BioClinica Express electronic data capture (EDC) and data management services to support their clinical trials world-wide. Onconova has a number of clinical-stage products and a growing number of pre-clinical candidates. These development stage compounds are novel small molecules for the treatment of a broad range of hematologic malignancies and solid tumors.

More... »

Mersana Therapeutics appoints Michael A. Metzger as executive VP, COO

Wednesday, April 20, 2011 11:46 AM

Michael A. Metzger has joined Mersana Therapeutics, a platform-based cancer therapeutics company, as executive vice president & chief operating officer. 

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs